spacer
home > ebr > summer 2018 > endonuclease compliance
PUBLICATIONS
European Biopharmaceutical Review

Endonuclease Compliance

A novel fermentative process, free of animal-based derivatives, uses endotoxin-free Bacillus amyloliquefaciens to economically produce the endonuclease from Serratia marcescens in high quantities. The new derivative is the first current Good Manufacturing Process (cGMP) product of its type, allowing its use in red biotechnology without regulatory restrictions.

Nucleases comprise a broad family of hydrolases that cleave nucleic acids. Several biotechnological applications have been reported, for example, in removing nucleic acids in biosynthetic processes to reduce viscosity associated to cell disruption or in the cost-effective elimination of nucleic acid impurities of a final (biosynthetic) product to comply with tight safety regulations. The production of the endonuclease from S marcescens has recently been successfully demonstrated in Bacillus subtilis − a gram-positive, endotoxin-free bacterium. Moreover, the fermentation is conducted in the absence of animal-based derivatives, thus, the novel derivative is an animal-free ingredient without the risk of bovine spongiform encephalopathy and transmissible spongiform encephalopathy (BSE/TSE). On that basis, the new endonuclease fulfils all cGMP requirements and may significantly broaden the applications of nucleases in biopharmaceuticals, promoting new markets and stimulating established ones.

Applying Nucleases

Nucleases are hydrolases that cleave the phosphodiester bonds between monomers of nucleic acids (DNA and RNA), digesting them into smaller oligonucleotides. In nature, they are responsible for the proper maintenance of nucleic acids in cells, keeping the genetic quality control and being actively involved in DNA replication and reparation. Some unspecific nucleases display the cleavage of all forms of nucleic acids, namely DNA and RNA, single- or double-stranded, linear or circular, and without any defined sequence-specificity. In the realm of red biotechnology and molecular biology sciences, such nucleases have become useful biocatalysts for a broad number of applications. A remarkable example is the purification of biopharmaceuticals – for instance, biosynthesised proteins, vaccines, etc – by removing the nucleic acid impurities generated along the bioprocess, thus saving costs associated to the downstream processing and purification units. Another useful application is the reduction of viscosity in biological samples caused by the presence of nucleic acids when cells are disrupted during the work-up steps.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dr Pablo Domínguez de María holds BScs in pharmacy and chemistry and a PhD in biocatalysis. He worked in the industry for 6.5 years at Evonik from and AkzoNobel BV, being involved in projects related to sustainable chemistry, organocatalysis, biorefineries, and biotech. In 2009, Pablo joined the RWTH Aachen University, Germany, as group leader, defending his habilitation in 2015. Since 2014, he is the CEO of Sustainable Momentum, a consultancy firm providing technical support in areas related to biorefineries, biotech, and sustainable chemistry. He has delivered several technical books, is co-inventor of some patents, and has published more than 100 scientific publications.

Dr Stefan Schoenert is Head of Strain and Process Development at c-LEcta. He was the developer of DENARASE nuclease and is responsible for development and improvement of biotech-relevant expression systems based on microorganisms including Bacillus sp, E coli, and Pichia pastoris and their use in production of enzymes and organic chemicals. Stefan has a PhD in biology from the University of Konstanz, Germany.
spacer
Dr Pablo Domínguez de María
spacer
spacer
spacer
Dr Stefan Schoenert
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Turkish Cargo maintains its steady growth.

According to the data obtained by WACD, the international air cargo information provider, in May; Turkish Cargo, the global air cargo brand providing service to 124 countries around the world, increased its tonnage rate by 7.1 percent, and grew substantially across the industry which shrank by 5.1 percent in the global air cargo market.
More info >>

White Papers

Orthogonal Approaches for the Analysis of Protein Sequence

Ludger Ltd

One of the most important classes of biopharmaceuticals is monoclonal antibodies. They are expressed from living cells, and are consequently subject to complex biochemical pathways. Not all of these routes are fully understood, and many are sensitive to the subtlest of environmental changes. Changes such as these can affect the final biopharmaceutical sequence, structure and post-translational modifications, not to mention any changes that may occur during further purification. This often means that the final product from one batch may be different from the last in another batch. Each batch is a complicated mix of similar molecules, and analysis of the degree of batch-to-batch variation is therefore very important to the establishment of the drug's safety for medicinal use and patient administration.
More info >>

 
Industry Events

ELRIG Drug Discovery 2019 – Looking Back to the Future

5-6 November 2019, ACC, Liverpool

Now in its 13th year, ELRIG’s flagship conference Drug Discovery 2019 will take place at ACC in Liverpool. This year’s focus, ‘A Look Back to the Future’ is planned to include plenary introductions assessing how we got to where we are now and setting the challenges for discovering the drugs of the future. These will be followed by cutting edge talks and examples of new directions in drug discovery. Our scientific programme will feature over 40 world-class speakers with 6 main session tracks. In partnership with key academic and charitable groups, we will also run joint disease and biology-oriented tracks focusing on the basic sciences that underpin successful drug discovery.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement